Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism

Alexander Solms1 · Stefan Willmann2 · Isabel Reinecke3 · Theodore E. Spiro4 · Gary Peters5 · Jeffrey I. Weitz6 · Wolfgang Mueck7 · Dirk Garmann2 · Stephan Schmidt8 · Liping Zhang5 · Keith A. A. Fox9 · Scott D. Berkowitz4

Published online: 23 April 2020
© The Author(s) 2020

Abstract
Anticoagulant plasma concentrations and patient characteristics might affect the benefit–risk balance of therapy. This study assessed the impact of model-predicted rivaroxaban exposure and patient characteristics on outcomes in patients receiving rivaroxaban for venous thromboembolism treatment (VTE-T) using data from the phase 3 EINSTEIN–DVT and EINSTEIN–PE studies. In the absence of measured rivaroxaban exposure, exposure estimates were predicted based on individual increases in prothrombin time (PT) and the known correlation between rivaroxaban plasma concentrations and PT dynamics. The composite efficacy outcomes evaluated were recurrent deep-vein thrombosis (DVT) and pulmonary embolism (PE) and recurrent DVT, PE and all-cause death; safety outcomes were major bleeding and the composite of major or non-major clinically relevant (NMCR) bleeding. Exposure–response relationships were evaluated using multivariate logistic and Cox regression for the twice-daily (BID) and once-daily (OD) dosing periods, respectively. Predicted rivaroxaban exposure and CrCl were significantly associated with both efficacy outcomes in the BID period. In the OD period, exposure was significantly associated with recurrent DVT and PE but not recurrent DVT, PE and all-cause death. The statistically significant exposure–efficacy relationships were shallow. Exposure–safety relationships were absent within the investigated exposure range. During both dosing periods, low baseline hemoglobin and prior bleeding were associated with the composite of major or NMCR bleeding. In conclusion, based on the underlying data and analysis, no reliable target window for exposure with improved benefit–risk could be identified within the investigated exposure range. Therefore, monitoring rivaroxaban levels is unlikely to be beneficial in VTE-T.

Keywords Drug monitoring · Exposure–response · Rivaroxaban · Venous thromboembolism

Isabel Reinecke is employed by Bayer AB in Solna, Sweden; this work was performed on behalf of Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany.

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s11239-020-02073-z) contains supplementary material, which is available to authorized users.
Highlights

- Employing multivariate regression approaches, post hoc exposure–response analyses were performed using data from the EINSTEIN–DVT/EINSTEIN–PE studies to assess the impact of model-predicted rivaroxaban exposure and patient characteristics on clinical outcomes.
- Model-predicted rivaroxaban exposure–response relationships with both efficacy and safety were shallow sloped or absent within the investigated exposure range.
- Monitoring rivaroxaban levels is unlikely to be beneficial when managing venous thromboembolism treatment.

Introduction

Rivaroxaban, an oral direct factor Xa inhibitor, is approved for several indications including venous thromboembolism (VTE) treatment (VTE-T), which includes the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE in adults [1].

Rivaroxaban was developed to provide predictable anticoagulation with fixed-dose administration, without the need to routinely measure drug levels or perform coagulation assays for dose adjustment. This approach is supported by the high bioavailability of rivaroxaban when administered with food, and the low potential for food and drug interactions, which minimize variability in rivaroxaban exposure [2–4].

Rivaroxaban doses for VTE-T were assessed in two large multicenter phase 2 trials: ODIXa–DVT (NCT00839163) [5] and the EINSTEIN–DVT Dose-Ranging Study (NCT00395772) [6]. The EINSTEIN–DVT (NCT00440193) and EINSTEIN–PE (NCT00439777) trials [7, 8] constituted the phase 3 program that led to the approval of rivaroxaban 15 mg twice daily (BID) for the first 21 days for the initial treatment of acute DVT and PE, followed by 20 mg once daily (OD) thereafter for longer-term treatment and for the prevention of recurrent DVT and PE [1].

Advanced age and impaired renal function are associated with increased rivaroxaban exposure [1, 9], and are also independent risk factors that affect the benefits and risks (e.g. bleeding) of anticoagulant therapy. In patients receiving anticoagulants for VTE-T, factors such as previous history of VTE and concurrent cancer treatment affect the risk of VTE and/or bleeding [10–13].

Because rivaroxaban exposure varies between patients, it has been a matter of debate whether therapeutic drug monitoring (i.e., plasma-concentration-based dose adjustment) may enhance the individual benefit–risk ratio of treatment [14]. Such treatment individualization requires a robust understanding and quantification of the association between exposure and safety and efficacy. Using data from the EINSTEIN–DVT/PE studies and individually predicted rivaroxaban exposure parameters, post hoc exposure–response analyses were performed to assess the impact of rivaroxaban exposure and patient characteristics on clinical outcomes in patients receiving rivaroxaban for VTE-T. The data reported here accompany the results of a similar analysis in which the impact of rivaroxaban exposure and patient characteristics on clinical outcomes were assessed in patients receiving rivaroxaban for VTE prevention.

Methods

Study design

Full details of the methodology and ethical conduct of EINSTEIN–DVT/PE have been published previously [7, 8]. Briefly, 8282 patients with acute symptomatic DVT or PE, with or without DVT, were randomized to receive rivaroxaban (15 mg BID for 21 days followed by rivaroxaban 20 mg OD thereafter [mean duration of treatment 208 days]) or standard therapy for ≤ 12 months (Table 1). Two composite efficacy outcomes were evaluated in the current exposure–response analysis: recurrent DVT and fatal/non-fatal PE; and recurrent DVT, fatal/non-fatal PE and all-cause death. Major bleeding and a composite of major or non-major clinically relevant (NMCR) bleeding were evaluated as safety outcomes (Table 1). Separate analyses were performed for the BID and OD dosing periods. The BID dosing period analysis included events occurring from the first until the last day of BID dosing or until 2 days after the last BID dose (for patients continuing or not continuing into the OD period, respectively). Analysis of the OD dosing period included events occurring from the first day of OD dosing until 2 days after the last OD dose.

Patient characteristics

Patient characteristics considered in the exposure–response evaluation (including potential risk factors for clinical outcomes) were identified a priori based on a literature review [12, 15–19] and experience in EINSTEIN–DVT/PE [7, 8]. Continuous variables, including age, were categorized to aid interpretation.
Table 1 Description of the studies and outcomes included in the exposure–response analyses

| Study             | EINSTEIN–DVT [7]                                                                 | EINSTEIN–PE [8]                                                                 |
|-------------------|----------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| Population        | Patients with acute, symptomatic DVT without symptomatic PE                      | Patients with acute, symptomatic PE with or without DVT                          |
| Total number of patients randomized | 8282                                                                                     |                                                                                  |
| Pertinent exclusion criteria | Concomitant use of strong CYP3A4 inhibitors (e.g., HIV protease inhibitors or systemic ketoconazole) or strong CYP3A4 inducers like rifampicin |                                                                                  |
| Rivaroxaban dose and regimen | 15 mg BID for 21 days followed by 20 mg OD for 3, 6 or 12 months at the investigator’s discretion |                                                                                  |
| Comparator dose and regimen | Standard therapy with enoxaparin 1.0 mg/kg BID and warfarin or acenocoumarol (INR 2.0–3.0) |                                                                                  |
| Maximum follow-up | 12 months                                                                                   |                                                                                  |
| Mean treatment duration | Rivaroxaban: 208 days                                                                     | Standard therapy: 204 days                                                        |
| Total number of patients for ER analysis | 4130 (15 mg BID phase)                                                                    | 3953 (20 mg OD phase)                                                            |
| Efficacy outcomes for ER analysis | 1. Composite of recurrent DVT or fatal/non-fatal PE                                           | 2. Composite of recurrent DVT, fatal/non-fatal PE and death from any cause       |
| Safety outcomes for ER analysis | 1. ISTH major bleedinga                                                                     | 2. Major or NMCRb bleeding                                                        |

*BID twice daily, CYP3A4 cytochrome P450 3A4, DVT deep vein thrombosis, ER exposure–response, HIV human immunodeficiency virus, INR international normalized ratio, ISTH International Society on Thrombosis and Haemostasis, NMCR non-major clinically relevant, OD once daily, PE pulmonary embolism

aISTH major bleeding was defined as: overt bleeding associated with a decrease in hemoglobin of ≥ 2 g/dL or leading to a transfusion of ≥ 2 units of packed red blood cells or whole blood; bleeding that occurred in a critical site; or bleeding contributing to death

bNMCR bleeding was defined as: overt bleeding that did not meet the criteria for major bleeding but was associated with medical intervention; unscheduled contact with a physician; interruption or discontinuation of a study drug; or discomfort or impairment of activities of daily life

Table 2 Results of the final exposure–response models

| Variables          | Efficacy (DVT/PE) | Efficacy (DVT/PE/all-cause death) | Safety (Major bleeding) | Safety (Major/NMCR bleeding) |
|--------------------|-------------------|-----------------------------------|-------------------------|------------------------------|
| **BID period**     |                   |                                   |                         |                              |
| Active malignancy at randomization† | n.s               | n.s                               | n.s                     | n.s                          |
| Age†               | n.s               | n.s                               | n.s                     | n.s                          |
| CrCl†              | X                 | X                                 | n.s                     | n.s                          |
| Best exposure      | C_{trough}        | C_{trough}                        | n.s                     | n.s                          |
| Other significant covariate | None             | None                             | Baseline hemoglobin     | Baseline hemoglobin, bleeding history, NSAID use |
| **OD period**      |                   |                                   |                         |                              |
| Active malignancy at randomization† | n.s               | n.s                               | n.s                     | n.s                          |
| Age†               | n.s               | X                                 | n.s                     | n.s                          |
| CrCl†              | n.s               | X                                 | n.s                     | n.s                          |
| Best exposure      | C_{trough}        | n.s                              | Baseline hemoglobin, bleeding history | Baseline hemoglobin, bleeding history, clinically relevant bleeding in the BID period |
| Other significant covariate | None             | None                             | Baseline hemoglobin, bleeding history | Baseline hemoglobin, bleeding history, clinically relevant bleeding in the BID period |

*BID twice daily, CrCl creatinine clearance, C_{trough} trough plasma concentration, DVT deep vein thrombosis, NMCR non-major clinically relevant, n.s. not significant, NSAID non-steroidal anti-inflammatory drug, OD once daily, PE pulmonary embolism

†Forced input variables

X denotes statistically significant exposure–response relationship (p ≤ 0.01)
Model-predicted rivaroxaban exposure

Because rivaroxaban plasma concentrations were not measured in the EINSTEIN studies, a previously reported integrated population pharmacokinetic (popPK) model, which was partly developed using data from the phase 2 DVT studies [5, 6, 20] was employed to predict individual rivaroxaban exposure estimates using patient characteristics known to influence rivaroxaban pharmacokinetics [21]. Trough plasma concentration (C_{trough}), maximum plasma concentration (C_{max}) and area under the plasma concentration–time curve from 0 to 24 h (AUC_{0–24}) at steady state were predicted for each patient based on individual characteristics (age, weight, renal function measured as calculated creatinine clearance [CrCl] using the Cockcroft–Gault equation, and sex) and rivaroxaban dose. Using patient characteristics alone to predict individual rivaroxaban exposure might not adequately reflect the expected variability; therefore, a new approach, to enhance model-predicted rivaroxaban exposures based on the collateral correlation between rivaroxaban plasma concentration and measured prothrombin time, was applied as described previously [22].

Exposure–response analyses were performed for all patients who received at least one dose of rivaroxaban. For the rivaroxaban OD dosing period, relationships between exposure metrics and clinical outcomes were explored using Kaplan–Meier plots.

Regression analyses

For the BID dosing period, exposure–response relationships were evaluated using logistic regression with application of penalized likelihood (Firth method) to avoid small-sample bias [23]. Time-to-event analysis was not expected to provide additional information in this context because the treatment duration was short (3 weeks). For the long-term OD dosing period, exposure–response relationships were analyzed using time-to-event Cox proportional regression. The analysis was conducted using R (version 3.3.0) and the logistf, survival, coxphf and pspline packages.

Relationships between rivaroxaban exposure metrics, patient characteristics and each of the efficacy and safety outcomes were quantified using the following methods. Initially, univariate regression analyses were performed using C_{trough}, C_{max} or AUC_{0–24} as independent variables, assuming a linear relationship for the continuous exposure measures (logistic regression) or a linear relationship between the exposure measures and the log hazard of outcome events (Cox proportional regression). The exposure metric most strongly associated with the occurrence of an event, indicated by the lowest Akaike information criterion (AIC) value generated by the univariate analyses, was then combined with the selected patient characteristics for VTE-T as independent variables for predicting the probability of the outcomes in multivariate regression analyses (the full model). Age and CrCl were expected to influence outcomes [1], and were, therefore, forced into the models regardless of their statistical significance. This forced inclusion was done to avoid bias in the variable selection process due to confounding variables, given that a patient’s CrCl and age are also correlated with rivaroxaban exposure. Active malignancy at randomization was an additional covariate forced into the model for the efficacy and safety analyses. With selected variables forced into the model, backward elimination, based on AIC values, was performed on the other variables until no further variable was removed. All statistically non-significant variables, with the exception of the forced input variables, were removed to generate the final model. Statistical significance refers to covariates, including exposure, with a likelihood ratio test p value no greater than 0.01.

If exposure was included in the final model, hazard ratios (HRs) or odds ratios (ORs) were generated for the variables in the final models and shown in forest plots. The reference category was the most-commonly observed category for the variable, except for region, for which Western Europe was set as the reference. For exposure metrics, the median value of each dose was set as the reference to represent the typical exposure in a patient at that dose level. The final models were used to simulate the probability of efficacy or safety events versus exposure in a typical patient population (i.e., with individual patient characteristics set to reference values).

Results

Patient characteristics

Supplemental Table 1 shows the patient characteristics selected for evaluation. Supplemental Table 2 shows the count and proportion of patients in the EINSTEIN–DVT/PE studies with each characteristic. Among the 4130 patients included in the BID dosing period, 63% were < 65 years of
age, 21% were 65–75 years of age, and 16% were > 75 years of age; 56% were male. Overall, 8% of these patients had CrCl < 50 mL/min and approximately 6% had active malignancy at randomization.

Rivaroxaban exposure predictions and event rates

Rivaroxaban exposure data were predicted in 4130 patients who participated in the BID dosing period and in 3953 patients who participated in the OD dosing period (Supplemental Table 3). The derived, model-based exposure metrics
showed moderate variability, with $C_{\text{trough}}$ being the most variable parameter (coefficient of variation: 43.0–52.8%). The predicted exposure metrics were all highly correlated (correlation coefficient $> 0.93$) within a given individual. The observed efficacy and safety outcome event rates are presented in Supplemental Table 4.

**Regression analyses**

Results of the final exposure–response models are summarized in Table 2.

**Exposure–efficacy analysis**

In the univariate regression analysis for efficacy, $C_{\text{trough}}$ was selected for further investigation based on AIC value (Supplemental Table 5). Cumulative event rates versus stratified $C_{\text{trough}}$ values for the OD dosing period are shown in Kaplan–Meier plots (Fig. 1a, b). There was no apparent trend between quartiles of $C_{\text{trough}}$ and event rates for the composite efficacy outcomes during the OD dosing period.

The occurrence of recurrent DVT or fatal/non-fatal PE events was significantly associated with decreasing $C_{\text{trough}}$ and CrCl during the BID dosing period (Fig. 2a) and with decreasing $C_{\text{trough}}$ during the OD dosing period (Fig. 2b). For both the OD and BID periods, the risk of recurrent DVT or fatal/non-fatal PE decreased with increasing rivaroxaban exposure. None of the other variables investigated were significantly associated with this efficacy outcome (Supplemental Table 6).

The occurrence of recurrent DVT, fatal/non-fatal PE or all-cause death was significantly associated with decreasing $C_{\text{trough}}$ and CrCl during the BID dosing period (Fig. 3a, Supplemental Table 6). During the OD dosing period, $C_{\text{trough}}$ was not significantly associated with this outcome [HR 0.99 (95% confidence interval (CI) 0.97–1.00)]; however, CrCl $< 50$ mL/min versus $> 80$ mL/min [HR 4.56 (95% CI 1.74–11.95)] and active malignancy at randomization [HR 5.61 (95% CI 3.15–10.01)] were associated with a significantly increased risk of this outcome (Supplemental Table 6).

Exposure–efficacy relationships were shallow or not significant. An increase from the 5th to the 95th percentile of rivaroxaban exposure was predicted to be associated with a decrease from 1.72% (95% CI 1.08–2.71) to almost zero (95% CI 0.03–0.41) in the probability of recurrent DVT or fatal/non-fatal PE during the BID dosing period (Fig. 2c) and from 4.13% (95% CI 1.85–8.61) to $< 0.5$% (95% CI 0.07–1.07) in a typical patient with CrCl 50–80 mL/min (Fig. 2d). During the OD dosing period, an increase in exposure from the 5th to the 95th percentile was predicted to reduce the probability of this efficacy outcome from 1.45%
The probability of recurrent DVT, fatal/non-fatal PE or all-cause death was predicted to decrease from 1.62% (95% CI 1.03–2.53) to almost zero (95% CI 0.03–0.38) (Fig. 3b) and from 4.3% (95% CI 2.06–8.48) to < 0.5% (95% CI 0.09–1.09) at 21 days in a typical patient with CrCl 50–80 mL/min (Fig. 3c) as rivaroxaban exposure increased from the 5th to the 95th percentile. No significant associations between rivaroxaban exposure and this efficacy outcome were observed during the OD treatment period.

**Exposure–safety analysis**

Following univariate regression analysis, $C_{\text{max}}$ was selected for further investigation in exposure–safety analyses for the BID dosing period. For the OD period, $C_{\text{max}}$ and AUC$_{0–24}$, were associated with the lowest AIC values and selected for further investigation for major bleeding and a composite of major or NMCR bleeding, respectively (Supplemental Table 5). Cumulative event rates versus stratified $C_{\text{max}}$ and AUC$_{0–24}$ values for the OD dosing period suggested that the cumulative event rate for major bleeding (Fig. 1c) and major or NMCR bleeding (Fig. 1d) increased as the rivaroxaban $C_{\text{max}}$ or AUC$_{0–24}$ value, respectively, increased.

However, in the context of a multivariate regression analysis, model-predicted exposure was not significantly associated with major bleeding or a composite of major or NMCR bleeding during either dosing period (Supplemental Table 7).

During the BID dosing period, low baseline hemoglobin (< 13 g/dL for men, < 12 g/dL for women) was significantly associated with major bleeding [OR 7.26 (95% CI 2.61–22.48)]. Low baseline hemoglobin [OR 2.61 (95% CI 1.89–3.59)], history of bleeding [OR 2.16 (95% CI 1.34–3.35)] and non-steroidal anti-inflammatory drug (NSAID) use [OR 2.24 (95% CI 1.47–3.32)] were significantly associated with major or NMCR bleeding (Supplemental Table 8).
During the OD dosing period, low baseline hemoglobin [HR 4.70 (95% CI 2.04–10.83)] and a history of bleeding [HR 4.87 (95% CI 2.02–11.75)] were significantly associated with major bleeding. Low baseline hemoglobin [HR 1.75 (95% CI 1.32–2.32)], prior clinically relevant bleeding in the BID dosing period (HR 2.65 (95% CI 1.72–4.08)) and history of bleeding [HR 2.22 (95% CI 1.53–3.23)] were significantly associated with major or NMCR bleeding (Supplemental Table 8).

Discussion

For patients receiving rivaroxaban for VTE-T, significant but shallow exposure–efficacy relationships were observed. This finding should be interpreted with caution because the number of events was small. In this situation, characterization of the respective exposure–response relationship is relatively imprecise in cases of no or weak-to-moderate exposure–response effect size. Given that the rate of major bleeding was low and no significant exposure–response relationship was observed, there is unlikely to be a strong exposure–response relationship within the studied exposure range. These findings are consistent with an exposure–response analysis of apixaban for VTE-T, in which the number of patients with either a thromboembolic or bleeding event was small and no statistically significant relationship between exposure and clinical outcomes could be detected [24].

Taken together with the primary study efficacy and safety outcome results [7, 8], these findings support the approved, fixed-dose rivaroxaban regimen for VTE-T. They also show that patient characteristics, such as a history of bleeding, low baseline hemoglobin and NSAID use, have a substantial impact on bleeding outcomes with rivaroxaban and are important in assessing individual bleeding risk. Renal function, measured as CrCl, had a modest effect on rivaroxaban exposure in the integrated popPK model, with age and body weight having a minor influence on exposure [21]. Indeed, the European label for rivaroxaban states that a dose reduction from 20 mg OD to 15 mg OD should be considered in patients with moderate or severe renal impairment [1]. It is advised that signs or symptoms of blood loss should be promptly evaluated in patients taking concomitant aspirin, platelet aggregation inhibitors or NSAIDs [1].

Limitations of this analysis include the paucity of direct pharmacokinetic measurements and consequent use of model-predicted exposure data, which could not fully reproduce the inter-patient variability expected in a real-world patient population. The exposure–response analyses were post hoc, and the phase 3 studies included were not designed to evaluate exposure–response relationships and the impact of patient characteristics on outcomes. Finally, these analyses were based on only the approved dosing regimen for VTE-T. To draw more reliable conclusions on the utility of a therapeutic drug monitoring treatment approach, and to establish a potential treatment algorithm that is trusted to improve individual patient treatment outcome, further systematic evaluation of data and methods and correlation with clinical events in outcomes trials would be needed.

Conclusions

In this analysis, model-predicted rivaroxaban exposure–response relationships were shallow or absent for both safety and efficacy outcomes. Based on the underlying studies, no reliable exposure target window with improved benefit–risk could be identified within the investigated exposure range and there was no evidence that the benefit–risk balance of rivaroxaban would be enhanced by implementing therapeutic drug monitoring as a routine measure [25]. These results support the approved, fixed-dose rivaroxaban regimens for VTE-T. However, as observed with other direct oral anticoagulants, evaluating patient characteristics, particularly renal function, also provides valuable information when considering treatment with rivaroxaban.

Acknowledgements This work was conducted at Bayer AG, Bayer U.S., LLC, and Janssen Research & Development, LLC. Emma Bolton of Oxford PharmaGenesis, Oxford, UK, provided medical writing support, which was funded by Bayer AG, Berlin, Germany. The authors would like to thank Xiaoyu Yan, Dagmar Kubitza and Martin Homering for their contributions related to the work described in this manuscript.

Author contributions All authors contributed to study concept and design, analysis and/or interpretation of data, critical writing and revising the manuscript. All authors approved the final version of the manuscript to be published.

Compliance with ethical standards

Conflict of interest This analysis, including its design, and the collection, analysis and interpretation of data, were funded by Bayer AG, Berlin, Germany, and Janssen Research & Development, LLC. Raritan, NJ, USA. The writing of the report and decision to submit the work for publication were carried out jointly by the authors, some of whom are employees of Bayer AG and Janssen Research & Development, LLC. All authors had access to the study data. Dirk Garmann, Wolfgang Mueck, Alexander Solms and Stefan Willmann are employees of Bayer AG; Isabel Reinecke is an employee of Bayer AB; Scott D. Berkowitz and Theodore E. Spiro are employees of Bayer U.S., LLC. This work was conducted within the scope of their employment, and no additional payment was received. Gary Peters and Liping Zhang are employees of Janssen Research & Development, LLC, and own stock in Johnson & Johnson. This work was conducted within the scope of their employment, and no additional payment was received. Keith A. A. Fox has received grants and honoraria relating to this work from Bayer AG and Janssen Research & Development, LLC, and he has re-
Informed consent

Informed consent was obtained from all individual persons included in the studies; details have been published previously [7, 8]. This article does not contain any studies with animals performed by any of the authors.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee; details have been published previously [7, 8]. This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the studies; details have been published previously [7, 8].

Open Access

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Bayer Pharma AG (2017) Rivaroxaban Summary of Product Characteristics. https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf. Accessed October 2019.

2. Mueck W, Schwers S, Stampfuss J (2013) Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J 11(1):10. https://doi.org/10.1186/1477-9560-11-10

3. Mueck W, Stampfuss J, Kubitza D, Becka M (2014) Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 53(1):1–16. https://doi.org/10.1007/s40262-013-0100-7

4. Sato M, Narukawa M (2015) Factors affecting intrasubject variability of PK exposure: absolute oral bioavailability and acidic nature of drugs. Int J Clin Pharmacol Ther 53(11):955–962. https://doi.org/10.5414/CP202399

5. Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S, ODIXa-DVT Study Investigators (2007) Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59–7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59–7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation 116(2):180–187. https://doi.org/10.1161/CIRCULATIONAHA.106.668020

6. Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A, Einstein-DVT Dose-Ranging Study investigators (2008) A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 112(6):2242–2247. https://doi.org/10.1182/blood-2008-05-160143

7. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounamaque H, Cohen A, Davidson BL, Piovella F, Schellong S (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499–2510. https://doi.org/10.1056/NEJMoa1007903

8. Buller HR, Prins MH, Lensing AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounamaque H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366(14):1287–1297. https://doi.org/10.1056/NEJMoa1113572

9. Ansell J, Hirsh J, Hylek E, Jacobson M, Palareti G (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133(6 Suppl):160S–198S. https://doi.org/10.1378/chest.08-0670

10. Lee AYY, Levine MN (2003) Venous thromboembolism and cancer: risks and outcomes. Circulation 107(23 suppl 1):I1–I7–I11. https://doi.org/10.1161/01.cir.0000150639.98514.6c

11. Agnelli G (2004) Prevention of venous thromboembolism in surgical patients. Circulation 110(24 Suppl 1):IV4–IV12. https://doi.org/10.1161/01.CIR.0000150639.98514.6c

12. Prandoni P, Lensing AW, Piccioni A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100(10):3484–3488. https://doi.org/10.1182/blood-2002-01-0108

13. Ay C, Kamphuisen PW, Agnelli G (2017) Antithrombotic therapy for prophylaxis and treatment of venous thromboembolism in patients with cancer: review of the literature on current practice and emerging options. ESMO Open 2(2):e000188. https://doi.org/10.1136/esmoopen-2017-000188

14. Chan N, Sager PT, Lawrence J, Ortel T, Reilly P, Berkowitz S, Kubitza D, Eikelboom J, Florian J, Stockbridge N, Rose M, Temple R, Seltzer JH (2018) Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants? Am Heart J 199:59–67. https://doi.org/10.1016/j.ahj.2017.10.002

15. Di Nisio M, Ageno W, Rutjes AW, Pap AF, Buller HR (2016) Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists. Thromb Haemost 115(2):424–432. https://doi.org/10.1160/th15-06-0474

16. Lamberts M, Lip GY, Hansen ML, Lindhardsen J, Olesen JB, Raunso J, Olsen AM, Andersson PK, Gerds TA, Fosbol EL, Torp-Pedersen C, Gislason GH (2014) Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort study. Ann Intern Med 161(10):690–698. https://doi.org/10.7326/m13-1581

17. Davidson BL, Verheijen S, Lensing AW, Gебel M, Brighton TA, Lyons RM, Rehm J, Prins MH (2014) Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. JAMA Intern Med 174(6):947–953. https://doi.org/10.1001/jamainternmed.2014.946

18. Bauersachs RM, Lensing AW, Prins MH, Kubitza D, Pap AF, Decousus H, Beyer-Westendorf J, Prandoni P (2014) Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. Thromb J 12:25. https://doi.org/10.1182/blood-2017-06-75960

19. Nieto JA, Solano R, Ruiz-Ribo MD, Ruiz-Gimenez N, Prandoni P, Kearon C, Monreal M (2010) Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from
Associations between model-predicted rivaroxaban exposure and patient characteristics…

20. Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F (2011) Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 50(10):675–686. https://doi.org/10.2165/11595320-00000000-00000

21. Willmann S, Zhang L, Frede M, Kubitza D, Mueck W, Schmidt S, Solms A, Yan X, Garmann D (2018) Integrated population pharmacokinetic analysis of rivaroxaban across multiple patient populations. CPT Pharmacomet Syst Pharmacol 7(5):309–320. https://doi.org/10.1002/psp4.12288

22. Solms A, Frede M, Berkowitz SD, Hermanowski-Vosatkva A, Kubitza D, Mueck W, Spiro TE, Willmann S, Yan X, Zhang L, Garmann D (2019) Enhancing the quality of rivaroxaban exposure estimates using prothrombin time in the absence of pharmacokinetic sampling. CPT Pharmacomet Syst Pharmacol 8(11):805–814. https://doi.org/10.1002/psp4.12444

23. King G, Zeng L (2001) Logistic regression in rare events data. Polit Anal 9(2):137–163. https://doi.org/10.1093/oxfordjournals.pan.a004868

24. Byon W, Sweeney K, Frost C, Boyd RA (2017) Population pharmacokinetics, pharmacodynamics, and exploratory exposure-response analyses of apixaban in subjects treated for venous thromboembolism. CPT Pharmacomet Syst Pharmacol 6(5):340–349. https://doi.org/10.1002/psp4.12184

25. European Medicines Agency Assessment Report for the Post-Authorisation Measure LEG 036.4 Xarelto. https://www.ema.europa.eu.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.